Penn cell therapy spinout Verismo Therapeutics has a new owner. Here's how the deal came together and why everyone is telling ...

PHILADELPHIA, Dec. 20, 2024 /PRNewswire/ -- Verismo Therapeutics, a clinical-stage CAR T company developing novel KIR-CAR platform technology, today announced the completion of a merger in which ...

Verismo Therapeutics has commenced the first patient dosing in its multicentre Phase I CELESTIAL-301 trial of SynKIR-310. The subject was dosed at the Sarah Cannon Research Institute of Colorado ...

University of Pennsylvania spinout Verismo Therapeutics is being acquired by South Korea-based HLB Group, which already owns an almost 50 percent stake in the firm, writes John George for the ...

Clinical-stage CAR T company dosed first patient for Phase 1 trial to evaluate SynKIR™-310, a new drug candidate for relapsed/refractory B cell Non-Hodgkin Lymphomas PHILADELPHIA, Jan. 10, 2025 ...